Sub-nanosized vanadate hybrid clusters maintain glucose homeostasis and restore treatment response in inflammatory disease in obese mice  

作　　者：Kun Chen Shengqiu Liu Yujun Wei 

机构地区：[1]South China Advanced Institute for Soft Matter Science and Technology,School of Emergent Soft Matter,South China University of Technology,Guangzhou 510641,China [2]Guangdong Provincial Key Laboratory of Technique and Equipment for Macromolecular Advanced Manufacturing,South China University of Technology,Guangzhou 510641,China [3]Guangdong Provincial Key Laboratory of Functional and Intelligent Hybrid Materials and Devices,South China University of Technology,Guangzhou 510641,China

出　　处：《Nano Research》2024年第3期1818-1826,共9页纳米研究（英文版）

基　　金：supported by the National Natural Science Foundation of China(No.22101086);the Natural Science Foundation of Guangdong Province(No.2021A1515010271);the Guangzhou Basic and Applied Basic Research Project(No.202201010052).

摘　　要：Obesity is closely related with insulin resistance and chronic inflammation.Here,we report that unsaturated lipid-modified polyoxovanadates(ULPOVs)can restrict weight gain of diet-induced obese mice and improve their glycemic control and obesity-associated inflammation.Oral administration of the sub-nanosized ULPOVs at a low dosage for 7 weeks reduces the body weight and almost normalizes the blood glucose levels of obese mice fed on a high-fat diet.ULPOV treatment increases the activity of the nuclear receptor peroxisome proliferator-activated receptorγ(PPARγ)and reduces intestinal caloric intake,which may be the main reason for blood sugar and body weight control.In addition to insulin-sensitizing,PPARγactivation induced by ULPOV treatment in obese mice with atopic dermatitis(AD)promotes the type 2 T helper(TH_(2))cell selective responses and therapeutic effects on immune dysregulation caused by obesity.These data suggest sub-nanosized polyoxovanadate clusters as a class of potential candidates to relieve symptoms accompanied by diet-induced obesity.

关 键 词：POLYOXOVANADATES lipid modification glucose homeostasis obesity inflammatory disease peroxisome proliferator-activated receptorγ(PPARγ) 

分 类 号：R589.2[医药卫生—内分泌]